Hemagglutination-inhibition and microneutralization antibody titers as mediators of protection for cell-based and recombinant influenza vaccines
Open Access
- 9 July 2026
- journal article
- Published by Springer Nature in npj Vaccines
- Vol. 11 (1)
Abstract
The proportion of relative influenza vaccine efficacy (rVE) mediated by post-vaccination hemagglutination inhibition (HAI) and microneutralization (MN) antibody titers has not been evaluated. We compared rVE by influenza vaccine type and HAI and MN antibody titer against symptomatic influenza A(H3N2) infection in a randomized immunogenicity trial of quadrivalent cell culture-based (ccIIV4), recombinant (RIV4), and egg-based (eIIV4) influenza vaccines in US healthcare personnel, and estimated proportions of rVE mediated by antibody titers using causal mediation analysis. Cumulative influenza A(H3N2) incidence was 3.2%, 1.3% and 1% among ccIIV, eIIV4 and RIV4 recipients, respectively. Age-adjusted rVE estimates were not statistically significant. Higher MN and HAI titers against A(H3N2) vaccine and circulating viruses explained 97.9% and 15.8%, respectively, of rVE for RIV4 compared with ccIIV4, versus 1.7% and 12.6% of rVE for eIIV4 compared with ccIIV4, indicating MN titers to be used as correlates of protection against A(H3N2) for comparisons between cell-based influenza vaccines.Keywords
Funding Information
- US Centers for Disease Control and Prevention (75D301-23-C-17596)
- US Centers for Disease Control and Prevention (75D301-23-C-17596)
- US Centers for Disease Control and Prevention (75D301-23-C-17596)
- US Centers for Disease Control and Prevention (75D301-23-C-17596)
- US Centers for Disease Control and Prevention (75D301-23-C-17596)
- US Centers for Disease Control and Prevention (75D301-23-C-17596)
- US Centers for Disease Control and Prevention (75D301-23-C-17596)
- US Centers for Disease Control and Prevention (75D301-23-C-17596)
- US Centers for Disease Control and Prevention (75D301-23-C-17596)
- US Centers for Disease Control and Prevention (75D301-23-C-17596)
- US National Institutes of Health (R01AI170116)
- US National Institutes of Health (R01AI170116)
- US National Institutes of Health (R01AI170116)
- US National Institutes of Health (R01AI170116)
- US National Institutes of Health (R01AI170116)
- US National Institutes of Health (R01AI170116)
- US National Institutes of Health (R01AI170116)
- US National Institutes of Health (R01AI170116)
- US National Institutes of Health (R01AI170116)
- US National Institutes of Health (R01AI170116)
- Research Grants Council (T11-705/21-N)
- Research Grants Council (T11-705/21-N)
- Research Grants Council (T11-705/21-N)
- Research Grants Council (T11-705/21-N)
- Research Grants Council (T11-705/21-N)
- Research Grants Council (T11-705/21-N)
- Research Grants Council (T11-705/21-N)
- Research Grants Council (T11-705/21-N)
- Research Grants Council (T11-705/21-N)
- Research Grants Council (T11-705/21-N)
This publication has 30 references indexed in Scilit:
- The role of influenza Hemagglutination-Inhibition antibody as a vaccine mediator in childrenVaccine, 2024
- Redirecting antibody responses from egg-adapted epitopes following repeat vaccination with recombinant or cell culture-based versus egg-based influenza vaccinesNature Communications, 2024
- Mediation and instrumental variable analyses for vaccine-induced antibody titer against influenza BVaccine, 2023
- Antigenic assessment of the H3N2 component of the 2019-2020 Northern Hemisphere influenza vaccineNature Communications, 2020
- Comparing influenza vaccine effectiveness between cell-derived and egg-derived vaccines, 2017–2018 influenza seasonVaccine, 2019
- Evaluation of correlates of protection against influenza A(H3N2) and A(H1N1)pdm09 infection: Applications to the hospitalized patient populationVaccine, 2019
- Low population serum microneutralization antibody titer against the predominating influenza A(H3N2) N121K virus during the severe influenza summer peak of Hong Kong in 2017Emerging Microbes & Infections, 2018
- Inverse odds ratio‐weighted estimation for causal mediation analysisStatistics in Medicine, 2013
- Comparison of hemagglutination inhibition assay, an ELISA-based micro-neutralization assay and colorimetric microneutralization assay to detect antibody responses to vaccination against influenza A H1N1 2009 virusJournal of Virological Methods, 2011
- Construction of confidence limits about effect measures: A general approachStatistics in Medicine, 2007